

FUTURE OF PREVENTION & TREATMENT



Peggy Lillis
Foundation
C. diff Education and Advocacy

Presenters

- ❖ Christian John Lillis, PLF (Moderator)
- ❖ Catherine Duff, Fecal Transplant Foundation
- ❖ Dr. Gerard Honig, Symbiotic Health
- ❖ Dr. Barbara McGovern, Seres Therapeutics
- ❖ Susan Watkins, Sanofi Pasteur
- ❖ Dr. Klaus Gottlieb, Synthetic Biologics

CDI Antibiotic Pipeline

- ❖ Surotomycin, acquired by Merck as part of its purchase of Cubist, is an investigational drug believed to target *C. diff* without impacting the rest of the gut microbiome.
 - Currently in Phase III Clinical Trials
 - Appears to lower rate of recurrence than vancomycin
- ❖ Cadazolid, is an investigational antibiotic, which also appears to tackle *C. diff*
 - Currently in Phase III clinical trials
 - In 2014, the FDA gave cadazolid Fast Track status